HER2-positive gastric cancer

被引：294

作者：

Boku, Narikazu ^{[1
]}

机构：

[1] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan

来源：

GASTRIC CANCER | 2014年 / 17卷 / 01期

关键词：

Stomach neoplasms; Trastuzumab; Receptor erbB-2; HER-2 proto-oncogene protein; GROWTH-FACTOR-RECEPTOR; ADVANCED BREAST-CANCER; IN-SITU HYBRIDIZATION; INDEPENDENT PROGNOSTIC-FACTOR; ANTIBODY-DRUG CONJUGATE; HER2 GENE AMPLIFICATION; RANDOMIZED PHASE-III; ADJUVANT CHEMOTHERAPY; TRASTUZUMAB EMTANSINE; PROTEIN EXPRESSION;

D O I：

10.1007/s10120-013-0252-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs, such as trastuzumab, which prolong overall survival and progression-free survival in HER2-positive breast cancer, may also be beneficial in patients with HER2-positive gastric cancer. Several studies have examined this possibility, such as the Trastuzumab for Gastric Cancer trial. In this context, the first part of this review provides an update on our knowledge of HER2 in breast and gastric cancer, including the detection and prognostic relevance of HER2 in gastric cancer. The second part of the review discusses the results of pivotal clinical trials that examined the potential for using trastuzumab to treat this disease. This section also summarizes the trials that have been conducted or that are underway to determine the optimal uses of trastuzumab in gastric cancer, including its use as monotherapy and continuation beyond disease progression. The final section discusses the future prospects of other anti-HER2 drugs, including lapatinib, trastuzumab emtansine, and pertuzumab, for the treatment of HER2-positive gastric cancer. The introduction of trastuzumab led to the establishment of a new disease entity, "HER2-positive gastric cancer," similar to HER2-positive breast cancer. It is expected that more anti-HER2 drugs will be developed and introduced into clinical practice to treat HER2-positive cancers, including gastric cancer.

引用

页码：1 / 12

页数：12

共 85 条

[51] Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction [J].

Phillips, B. E. ;

Tubbs, R. R. ;

Rice, T. W. ;

Rybicki, L. A. ;

Plesec, T. ;

Rodriguez, C. P. ;

Videtic, G. M. ;

Saxton, J. P. ;

Ives, D. I. ;

Adelstein, D. J. .

DISEASES OF THE ESOPHAGUS, 2013, 26 (03) :299-304

[52] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[53]

Rech J, 2006, ANN ONCOL, V17, P314

[54] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].

Romond, EH ;

Perez, EA ;

Bryant, J ;

Suman, VJ ;

Geyer, CE ;

Davidson, NE ;

Tan-Chiu, E ;

Martino, S ;

Paik, S ;

Kaufman, PA ;

Swain, SM ;

Pisansky, TM ;

Fehrenbacher, L ;

Kutteh, LA ;

Vogel, VG ;

Visscher, DW ;

Yothers, G ;

Jenkins, RB ;

Brown, AM ;

Dakhil, SR ;

Mamounas, EP ;

Lingle, WL ;

Klein, PM ;

Ingle, JN ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684

[55] The basic biology of HER2 [J].

Rubin, I ;

Yarden, Y .

ANNALS OF ONCOLOGY, 2001, 12 :3-8

[56] Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)] [J].

Sawaki, Masataka ;

Tokudome, Nahomi ;

Mizuno, Toshiro ;

Nakayama, Takahiro ;

Taira, Naruto ;

Bando, Hiroko ;

Murakami, Shigeru ;

Yamamoto, Yutaka ;

Kashiwaba, Masahiro ;

Iwata, Hiroji ;

Uemura, Yukari ;

Ohashi, Yasuo .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (05) :709-712

[57] Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? [J].

Sbitti, Yassir ;

Essaidi I, Ismail ;

Debbagh, Adil ;

Kadiri, Habiba ;

Oukabli, Mohamed ;

Moussaid, Yassine ;

Slimani, Khaoula ;

Fetohi, Mohamed ;

Elkaoui, Hakim ;

Albouzidi, Abderrahmane ;

Mahi, Mohamed ;

Ali, Abdelmounaim Ait ;

Ichou, Mohamed ;

Errihani, Hassan .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2011, 9 :112

[58] A V-ERBB-RELATED PROTOONCOGENE, C-ERBB-2, IS DISTINCT FROM THE C-ERBB-1/EPIDERMAL GROWTH FACTOR-RECEPTOR GENE AND IS AMPLIFIED IN A HUMAN SALIVARY-GLAND ADENOCARCINOMA [J].

SEMBA, K ;

KAMATA, N ;

TOYOSHIMA, K ;

YAMAMOTO, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (19) :6497-6501

[59]

Shitara K, 2012, GASTRIC CANCER, V15, P245, DOI [10.1007/s10120-011-0101-x, 10.1007/s10120-012-0179-9]

[60] Adjuvant Trastuzumab in HER2-Positive Breast Cancer [J].

Slamon, Dennis ;

Eiermann, Wolfgang ;

Robert, Nicholas ;

Pienkowski, Tadeusz ;

Martin, Miguel ;

Press, Michael ;

Mackey, John ;

Glaspy, John ;

Chan, Arlene ;

Pawlicki, Marek ;

Tamas Pinter ;

Valero, Vicente ;

Liu, Mei-Ching ;

Sauter, Guido ;

von Minckwitz, Gunter ;

Visco, Frances ;

Bee, Valerie ;

Buyse, Marc ;

Bendahmane, Belguendouz ;

Tabah-Fisch, Isabelle ;

Lindsay, Mary-Ann ;

Riva, Alessandro ;

Crown, John .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14) :1273-1283

← 1 2 3 4 5 6 7 8 9 →